T1	Participants 85 133	very platinum-sensitive ovarian cancer patients:
T2	Participants 234 302	patients with very platinum-sensitive recurrent ovarian cancer (ROC)
T3	Participants 414 526	women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies.
T4	Participants 1819 1860	patients with very platinum-sensitive ROC
T5	Participants 708 737	patients with a TFI>24 months
